Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
Dow
Merck
Johnson and Johnson

Last Updated: December 3, 2022

Details for Patent: 8,557,852


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,557,852 protect, and when does it expire?

Patent 8,557,852 protects BEVYXXA and is included in one NDA.

This patent has thirty-two patent family members in twenty countries.

Summary for Patent: 8,557,852
Title:Methods of using crystalline forms of a salt of a factor Xa inhibitor
Abstract: The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa. ##STR00001##
Inventor(s): Grant; Craig (Burwell, GB), Kanter; James P. (San Ramon, CA), Langlands; Graeme (Soham, GB)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/550,291
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,557,852

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing PROPHYLAXIS OF VENOUS THROMBOSIS See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing PROPHYLAXIS OF VENOUS THROMBOSIS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,557,852

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 056787 See Plans and Pricing
Argentina 106960 See Plans and Pricing
Austria 549317 See Plans and Pricing
Australia 2006311544 See Plans and Pricing
Brazil PI0618362 See Plans and Pricing
Canada 2627086 See Plans and Pricing
China 101304971 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
Boehringer Ingelheim
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.